CA Patent

CA3206184A1 — Treatment of migraine

Assigned to Allergan Pharmaceuticals International Ltd · Expires 2022-06-30 · 4y expired

What this patent protects

The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in pati…

USPTO Abstract

The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.

Drugs covered by this patent

Patent Metadata

Patent number
CA3206184A1
Jurisdiction
CA
Classification
—
Expires
2022-06-30
Drug substance claim
No
Drug product claim
No
Assignee
Allergan Pharmaceuticals International Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.